3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
enzalutamide
94
Magnetic Resonance Spectroscopy
86
Specimen Handling
66
Prednisone
66
Androgen Antagonists
60
Abiraterone Acetate
58
apalutamide
56
Radiosurgery
53
darolutamide
48
Radiotherapy
47
Leuprolide
47
abiraterone
46
Docetaxel
43
Pluvicto
32
Radiation
31
Biopsy
31
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
30
Surveys and Questionnaires
29
relugolix
28
pembrolizumab
26
gallium 68 PSMA-11
26
Standard of Care
26
Triptorelin Pamoate
25
Goserelin
25
bicalutamide
23
Gonadotropin-Releasing Hormone
23
Brachytherapy
21
Carboplatin
20
cabazitaxel
19
X-Rays
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
gadoterate meglumine
×
1 year
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled